Boehringer releases positive results from two breast cancer trials of afatinib

December 15, 2014 3:23 PM

11 0

Germany-based Boehringer Ingelheim has reported positive results from two trials (LUX-Breast 1 and LUX-Breast 3) evaluating afatinib to treat patients with breast cancer.

The Phase III LUX-Breast 1 trial compared afatinib plus vinorelbine (experimental arm) with trastuzumab plus vinorelbine in patients with HER2-positive metastatic breast cancer after failure of prior trastuzumab-based therapy.

Read more

To category page